The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function

Journal of Sexual Medicine

Volumn 8, Issue 11, 2011, Pages 3066-3074

  Pinsky, Michael R ^a   Gur, Serap ^a   Tracey, Anthony J ^a   Harbin, Andrew ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

5 alpha reductase inhibitors; Benign prostatic hypertrophy; Dihydrotestosterone; Dutasteride; Erectile function; Sexual dysfunction

Indexed keywords

ACETYLCHOLINE; ANDROSTANOLONE; COLLAGEN; DRINKING WATER; DUTASTERIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; CORPUS CAVERNOSUM; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; HORMONE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LONG TERM CARE; MALE; MUSCLE CONTRACTILITY; MUSCLE RELAXATION; NERVE STIMULATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT;

EID: 80255127536     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02425.x     Document Type: Article

References (20)

1. Da Silva FC. Benign prostatic hyperplasia: Natural evolution versus medical treatment. Eur Urol 1997;32(2 suppl):34-7.
2. Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008;5:2917-24.
3. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
4. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.
5. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
6. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999;83:327-33.
7. Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007;19:386-92.
8. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29:17-25.
9. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
10. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-88.
11. Lu YL, Kuang L, Zhu H, Wu H, Wang XF, Pang YP, Wang NJ, Yu DL. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor. Asian J Androl 2007;9:843-7.
12. Ferrini MG, Rivera S, Moon J, Vernet D, Rajfer J, Gonzalez-Cadavid NF. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med 2010;7:3033-44.
13. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002;7:262-76.
14. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002;6:283-94.
15. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006;8:3-9.
16. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
17. Traish AM, Netsuwan N, Daley J, Padman-Nathan H, Goldstein I, Saenz de Tejada I. A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1995;153:222-7.
18. Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997;18:26-31.
19. Tsang S, Wong SS, Wu S, Kravtsov GM, Wong TM. Testosterone-augmented contractile responses to alpha1- and beta1-adrenoceptor stimulation are associated with increased activities of RyR, SERCA, and NCX in the heart. Am J Physiol Cell Physiol 2009;296:C766-82.
20. Traish AM, Hassani J, Guay AT, Zitmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-84.